Vanda Pharmaceuticals (VNDA) Return on Sales Growth (5y) (2015 - 2026)

Vanda Pharmaceuticals (VNDA) Return on Sales Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 472.75 Bn 467.96 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.14 Bn 114.89 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.94 Bn 50.76 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn
10 Vanda Pharmaceuticals 315.44 Mn 113.13 Mn 48.56 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.00
Dec 31, 2025 -3.00
Sep 30, 2025 -1.00
Jun 30, 2025 -1.00
Mar 31, 2025 -1.00
Dec 31, 2024 0.00
Sep 30, 2024 -2.00
Jun 30, 2024 0.00
Mar 31, 2024 0.00
Dec 31, 2023 0.00
Sep 30, 2023 0.00
Jun 30, 2023 0.00
Mar 31, 2023 0.00
Dec 31, 2022 0.00
Sep 30, 2022 0.00
Jun 30, 2022 0.00
Mar 31, 2022 0.00
Dec 31, 2021 0.00
Sep 30, 2021 0.00
Jun 30, 2021 0.00